Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Nu.Q® Cancer Brochure

Tuesday, January 23, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article presents information regarding the Nu.Q® Cancer Test and its prognostic value. It references related articles and publications but does not provide detailed insights into specific results or findings. The content appears to be promotional in nature, encouraging subscriptions for updates.
Price reaction · baseline $20.3 (2024-01-23T15:33:00.000Z) · hit during market hours · 9 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+4.4%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields
ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q cancer test prognostic value Volition
Last updated: Jan 23, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk